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Background. CCL28 (MEC) binds to CCR3 and CCR10 and recruits IgA-secreting plasma cells (IgA-ASC) in the mucosal lamina
propria (MLP). Mucosal HIV-specific IgA are detected in HIV-infection and exposure. The CCL28 circuit was analyzed in HIV-
infected and-exposed individuals and in HIV-unexposed controls; the effect of CCL28 administration on gastrointestinal MLP
IgA-ASC was verified in a mouse model. Methodology/Findings. CCL28 was augmented in breast milk (BM) plasma and saliva
of HIV-infected and –exposed individuals; CCR3+ and CCR10+ B lymphocytes were increased in these same individuals.
Additionally: 1) CCL28 concentration in BM was associated with longer survival in HIV vertically-infected children; and 2)
gastro-intestinal mucosal IgA-ASC were significantly increased in VSV-immunized mice receiving CCL28. Conclusions. CCL28
mediates mucosal immunity in HIV exposure and infection. CCL28-including constructs should be considered in mucosal
vaccines to prevent HIV infection of the gastro-intestinal MLP via modulation of IgA-ASC.
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INTRODUCTION
Migration of IgA-secreting plasma cells into the mucosal lamina
propria (MLP) was recently shown to be correlated with specific
chemokines and chemokine receptors [1–13]. Thus, IgA-expres-
sing plasma blasts and plasma cells (IgA-ASC) are characterized by
a number of surface receptor proteins, including CCR9, CCR3,
and CCR10, that are ligated by specific chemokines. In particular,
it has been shown that CCR9 ligates the CC chemokine CCL25
(also known as thymus-expressed chemokine, or TECK) [4,10],
whereas both CCR10 and CCR3 bind a second CC chemokine
named CCL28 (also known as mucosae-associated epithelial
chemokine, or MEC) [1,5,10,12]. These interactions induce the
migration and the recruitment of IgA-ASC in the MLP. CCL25
was shown in a mouse model to mostly attract a subpopulation of
IgA-ASC associated with the small intestine [4,6,10]. CCL28 is
more widely expressed and potently chemoattracts IgA-ASC
originating from diverse mucosal lymphoid organs, as well as from
intestinal and extra intestinal tissues, in every studied mucosal
effector site-including the mammary and salivary glands-both in
mice and humans [1–7,9–12,14,15]. Thus, the CCL28-CCR10/
CCR3 circuit is considered to be a unifying system that plays
a major role in the homing of plasma blasts and plasma cells at
mucosal effector sites [3,5,13]. Interestingly, these chemotactic
abilities are limited to IgA-ASC as the migration of neither IgM
nor IgG ASC is stimulated by the CCL28-CCR10/CCR3 or the
CCL25-CCR9 systems [1–13]. The CCL28-CCR10/CCR3
circuit is also endowed with other interesting peculiarities. Thus,
CCL28 has a potent antimicrobial activity directed toward both
Gram-positive and Gram-negative microorganisms [3]. Addition-
ally, this chemokine is expressed by bone marrow stromal cells,
suggesting that the interaction of CCL28 with CCR10+/CCR3+
B cells may contribute to the integration between the mucosal and
the systemic immune responses [3].
High concentration of mucosal HIV-specific IgA have repeatedly
been observed in HIV-infected individuals [16–19] and have also
been suggested to characterize HIV sexually-exposed but uninfected
individuals (Exposed Seronegatives or ESN) [20–23]. Thus, HIV-
specific IgA were described to be present in saliva, cervico-vaginal
secretions, and breast milk from both HIV-infected and ESN
individuals in Europe, Asia and Africa by most [20–24], but not all
[25] authors. To investigate whether the presence of high
concentrations of mucosal HIV-specific IgA could be explained by
an upregulation of the chemokine circuits involved in mucosal
homing of IgA-ASC, we first measured CCL25 andCCL28 in breast
milk of a well-characterized cohort of HIV-infected breast feeding
mothers from Zambia. Results showing a significantly augmented
concentration of CCL28 in HIV IgA-positive milk encouraged us to
analyze CCR3-, CCR9-, and CCR10-expressing cells as well as the
mucosal concentration of CCL25 and CCL28 in ESN subjects and
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their HIV-infected partners. Results were compared to those seen in
HIV-unexposed individuals. Finally, as it was recently shown that
the privileged site of HIV replication during primary infection is the
gastro-intestinal (GI) mucosa, and IgA could protect this mucosa, we
verified whether the administration of CCL28 would result in
a significant modulation of IgA in the GI tract using an animal model
undergoing immunization with a VSV construct in the presence/
absence of CCL28. Results herewith indicate a pivotal role for
CCL28 in the modulation of mucosal immunity in HIV exposure
and infection and suggest a usefulness of CCL28-containing
adjuvants in the development of HIV vaccines.
MATERIALS AND METHODS
Study population
Breast milk samples were collected from 65 HIV-infected women
enrolled in a breastfeeding study in Lusaka, Zambia [26]. The
samples were selected to include 15 women who transmitted and 50
women who did not transmit HIV to their infant. Milk samples were
collected by manual expression between 1 and 5 weeks post-partum.
Milk samples from 9 uninfected Zambian women were included as
controls. All women signed informed consent to participate.
Blood samples and saliva were collected from 39 HIV-exposed
but uninfected heterosexual partners of HIV-infected individuals
(ESN)(27 females; 12 males). The inclusion criteria for the ESN
was a history of multiple unprotected sexual episodes (with the
same HIV-seropositive partner) for $4 years at the time of
enrollment, with at least 8 episodes of at-risk intercourse within the
4 months before study entry, and an average of 30 reported
unprotected sexual contacts per year (range 18 to .100). Forty
age-matched HIV-infected patients (HIV+) and 30 age- and sex-
matched healthy volunteer controls (HC), without any known risk
factor for HIV-infection, were studied as well. All ESN and HIV-
infected patients underwent in-depth clinical and laboratory
evaluation that did not reveal any concomitant infectious or
gynecologic problems. All individuals (ESN, HIV+, and HC) had
been longitudinally followed for .4 years before the study by the
Department of Obstetrics and Gynecology, Santa Maria Annun-
ziata Hospital, Florence. This allowed us to exclude from the study
ESN and HC in whom sexually transmitted diseases or any other
pathology was reported during that time period. Each subject
signed an informed consent form that was approved by the Ethical
committee of the S. M. Annunziata Hospital.
Breast milk preparation
All milk was processed within 4 hours of collection. Milk was
centrifuged at 400g and the cell pellet removed. The supernatant
and lipid portions were mixed together before aliquoting and were
stored at 270uC until use.
Blood sample collection and separation of PBMC
Whole blood was collected by venipuncture in Vacutainer tubes
containing EDTA (ethylenediaminetetraacetic acid) (Becton Dick-
inson, Rutherford, NJ). Peripheral blood mononuclear cells
(PBMC) were separated on lymphocyte separation medium
(Organon Teknica, Durham, NC) and washed twice in phos-
phate-buffered saline (PBS; Organon Teknica). The number of
viable leukocytes was determined by trypan blue exclusion. All
analyses were performed on freshly collected cells.
Immunophenotypic analysis
Surface receptors were evaluated using 50 ml of EDTA peripheral
blood. Cells were incubated for 30 min at 4uC with the following
flourochrome-labeled mAbs: CD19- R-phycoerythrin-Cyanine 5
Tandem–PE-Cy5 (mouse IgG1 isotype, Beckman Coulter, Full-
erton CA), CCR3-Phycoerythrin and CCR9-Fluorescein (mouse
IgG2a isotype, R&D Systems, Minneapolis, MN). After in-
cubation, erythrocyte lysis and fixation of marked cells was
performed using the Immuno-Prep EPICS Kit (Coulter Electron-
ics) and Q-prep Work Station (Coulter Electronics, Miami Lakes,
FL).. CCR10 expression was evaluated by indirect immunofluo-
rescence staining on PBMC: by incubating 250,000 cells with
a goat anti human CCR10 (diluted 1:25) (Capralogics Inc.,
Hardwick MA). After 30 min at 4uC, the cells were washed and
further incubated for 30 min at 4uC with 10 ml porcine anti-goat
IgG conjugated with PE (R&D Systems, Minneapolis, MN). After
this incubation cells were washed and fixed in 1% formaldehyde.
Cytometric analyses were performed using an EPICS XL flow
cytometer (Beckman-Coulter Inc., Miami, FL) equipped with
a single 15 mW argon ion laser operating at 488 nm interfaced
with 486 DX2 IBM computer. Data were collected using linear
amplifiers for forward and side scatter and logarithmic amplifiers
for FL1, FL2 and FL4. Samples were first run using isotype control
or single fluorochrome-stained preparations for color compensa-
tion. For each sample, multiparametric data were acquired for
100,000 events.
ELISA assays
CCL25 and CCL28 concentration was evaluated in breast milk,
plasma, and saliva using commercial ELISA kits (R&D Systems,
Minneapolis, MN) and following the procedures suggested by the
manufacturer. Chemokine production was calculated from a stan-
dard curve of the corresponding recombinant human chemokine.
Measurement of HIV-specific IgA
Breast milk concentration of IgA was measured after the thawed
stored samples had been centrifuged at 250,00 RCF for 30 minutes
at 4uC to remove the lipid layer [21]. All samples were processed in
the same way without access to information about the other
laboratory and clinical parameters. The supernatants were diluted
1:5000 in sterile saline solution or PBS just before use. HIV-specific
IgA in breast milk and saliva were measured using a modified
Calypte Biomedical HIV-1 enzyme immunoassay (EIA) (Calypte
Biomedical Corporation, Berkeley, CA) based on a recombinant
HIV-1 envelope protein as previously described [20].
Experiments in mice
1) Cloning of CCL28 The CCL28 murine chemokine gene was
digested with AgeI from the pORF-mCCL28 plasmid (InvivoGen,
San Diego, CA, USA) and a blunt end was produced with T4
DNA polymerase. Following digestion with NheI, the resulting
410 bp fragment was inserted into pCpG expression vector
(InvivoGen), which had been digested with ScaI/NheI.
2) Recombinant VSV. Recombinant viruses were recovered as
described previously [27]. Briefly, BHK-21 cells were grown to 50%
confluence and infected at a multiplicity of infection (MOI) of 10 with
vTF7-3, a vaccinia virus expressing T7 RNA polymerase [28]. One
hour after infection, cells were transfected with 10 mg of pVSVNX2
[29], kindly provided by John Rose (Yale University, New Haven,
CT), 3 mg of pBS-N, 5 mg of pBS-P and 2 mg of pBS-L. After 48 h,
cell supernatants were added to fresh BHK-21 cells and the recovery
of recombinant infectious VSV was performed 48 h later and
confirmed by development of cytopathic effect. The recombinant
VSV were propagated in BHK-21 cells and stored at 280uC.
3) Immunization procedures. Inbred female BALB mice
(Charles River Laboratories, Calco Italy), 6–8 weeks old, were
HIV MEC-CCL28 Mucosal Immunity
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utilized. Mouse colonies were maintained on a 12-h light-dark
cycle in cages of 5 animals with water and food provided ad
libitum. Different groups of mice (5 mice/group) were immunized
as follows: group 1=VSV alone (16105/mouse); group 2=VSV
(16105/mouse)+CCL28 (50 mg/mouse); group 3=CCL28 alone
(50 mg/mouse); group 4= saline alone (negative control group).
VSV was administrated intraperitoneally; CCL28 was adminis-
trated intramuscularly. Mice were immunized on day 0, boosted
on day 14, and sacrificed on day 28.
4) Immunohystochemistry analyses. Tissues obtained
from the colon of mice (2-cm specimens from the anus toward the
left colon) were fixed in buffered-formalin for 24 hours at room
temperature and then embedded in paraffin. Haematoxylin-eosin
stained sections were used for histological evaluation. The
evaluation of CD138+ plasmacells was performed on 3 mm
paraffin embedded selides; the sections were dewaxed in xylene,
rehydrated in an ascendent ethanol scale and pre-treated in
a microwave oven (two cycles for 5 minutes each at 780W, in
EDTA buffer, pH8). Endogen biotin and aspecific signals were
blocked by using the appropriate reagents. For immunohisto-
chemistry, a rat anti-mouse Syndecan-1 antibody (CD138, dilution
1:250, R&Dsystems, USA) was used; slides were incubated for two
hours at room temperature in a humid chamber; washed in PBS
and then revealed by biotinylated anti rat IgG (dilution 1:50, one
hour incubation, Vector Laboratories, USA) followed by ZyMax
Streptavidin HRP Conjugated (dilution 1:500, 30 minutes in-
cubation, Zymed, USA). The chromogen was 3,39-diaminobenzi-
dine free base (DAB). Negative controls were obtained by omission
of the primary antibody. The quantitative evaluation of immu-
nostaining, was performed by counting positive cells in 15 High-
Power Fields (the mean of values was considered). The evaluation
of IgA+ plasmacells was made on 3 mm paraffin embedded selides;
the sections were dewaxed in xylene, rehydrated in an ascendent
ethanol scale and pre-treated in a microwave oven (two cycles for
5 minutes each at 780W, in EDTA buffer, pH8). Endogen biotin
and aspecific signals were blocked by using the appropriate
reagents. For immunohistochemistry, a goat anti-mouse IgA
(dilution 1:400, AbD Serotec) was used; slides were incubated
for two hours at room temperature in a humid chamber; washed
in PBS and then revealed by biotinylated anti goat IgG (dilution
1:50, one hour incubation, R&Dsystems, USA) followed by
Streptavidin HRP Conjugated (ready to use, 30 minutes in-
cubation, R&Dsystems, USA). The chromogen was 3,39-diami-
nobenzidine free base (DAB).
Statistical analyses
Parameters were compared across groups using nonparametric
tests (Mann-Whitney) unless normally distributed, in which case
two-tailed T-tests were used. Correlations were calculated using
Figure 1. CCL28 concentration in breast milk of HIV-infected, HIV-exposed, and healthy women from Zambia. CCL28 concentration (pg/ml) in
breast milk from Zambian women enrolled in the Zambia Exclusive Breastfeeding Study (ZEBS). Results from HIV-seronegative controls; HIV-infected
women who did not have HIV-specific IgA in breast milk; and HIV-infected women with HIV-specific IgA in breast milk are shown. The boxes stretch
from the 25th to the 75th percentile; the line across the boxes indicates the median value; the line stretching from the box reaches the largest and the
smallest values detected in each group. Statistically significant differences are indicated.
doi:10.1371/journal.pone.0000969.g001
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the Spearman rank order coefficient. Kaplan-Meier analysis and
log-rank testse were used to compare mortality across groups.
Statistical analyses were performed using the SPSS statistical
package (SPSS Inc. Chicago, Illinois, USA).
RESULTS
CCL28 and HIV-specific IgA in breast milk from HIV-
infected women
CCL28 concentrations in breast milk were 2 log higher than that
observed in saliva and almost 3 log higher than that observed in
plasma Concentrations of CCL28 in breast milk were higher in
milk from 65 HIV-infected women (median 288,480 pg/ml) than
in milk from 9 uninfected women (median 86,170 pg/ml) but this
did not reach significance (p= 0.11) presumably due to small
numbers of uninfected women. Among HIV-infected women,
CCL28 concentrations in breast milk were nevertheless signifi-
cantly higher among 34 women who also had HIV-specific IgA
detected in their milk (median 354,012 pg/ml) compared to 31
women who did not have HIV-specific IgA detected (median
190,640 pg/ml) (p = 0. 012) (Figure 1).
CCL28 concentrations in breast milk from HIV-infected
women were not associated with maternal CD4 count, plasma
viral load, or breast milk viral load. CCL28 concentrations in
breast milk were not statistically different among 15 women who
transmitted HIV to their infants (median 288,480 pg/ml)
compared to 50 women who did not (median 291,227 pg/ml).
A significant association was nevertheless detected between
CCL28 concentration in breast milk and survival of HIV-infected
children. Among the 15 HIV-infected children, those 7 who died
in the first 18 months of life had mothers with lower BM
concentrations of CCL28 (median 146,995 pg/ml) than those 8
infants who survived past this age (median 349,472 pg/ml). Based
on Kaplan-Meier survival curves, those HIV-infected children
whose mothers had CCL28 concentrations less than median in the
population (288,480 pg/ml) were more likely to die in the first
18 months of life than those whose mothers had CCL28
concentrations in breast milk greater or equal to the median (log
rank p-value = 0. 038).
CCL28 in plasma and saliva of ESN, HC, and HIV
individuals
CCL28 concentration was measured in plasma of 39 ESN, 40
HIV-infected individuals, and 30 HIV-uninfected healthy con-
trols. Results showed that this IgA-secreting cells chemotactic
factor was increased in plasma of ESN and HIV patients
compared to HC. Thus, median CCL28 plasma concentrations
were HIV=379; ESN=332 pg/ml; HC=185 pg/ml (ESN vs.
HC p=0.039). These results are shown in Figure 2A. In contrast,
Figure 2. CCL28 concentration in plasma and saliva of HIV-infected, HIV-exposed, and healthy Italian individuals. CCL28 concentration (pg/ml) in
plasma (A) and in saliva (B) of 39 HIV-exposed seronegative individuals (ESN), 40 HIV-infected individuals (HC), and 30 HIV-uninfected healthy controls
(HC). Median values, standard deviations, and statistically significant differences are indicated.
doi:10.1371/journal.pone.0000969.g002
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no differences in the concentration of CCL25 were seen among
the three groups of individuals examined (data not shown).
The concentration of CCL28 was also significantly increased in
saliva of ESN and HIV individuals compared to healthy controls.
Median CCL28 salivary concentrations were: HIV=3379 pg/ml;
ESN=2259 pg/ml; HC=364 pg/ml (HIV vs. HC p=0.001;
ESN vs. HC p=0.007)(Figure 2B). CCL25 was comparable in
ESN, HIV, and HC (data not shown).
CCR3- and CCR10- expressing CD19+ cells in ESN,
HC, and HIV individuals
Flow cytometry evaluation of CCR3 and CCR10 was performed
in CD3+, CD14+ and CD19+ peripheral blood mononuclear
cells. Results showed that the CCR3- and CCR10- expressing
CD3+ and CD14+ cells were comparable in the three groups
examined. In contrast, the percentage of CD19+/CCR3+ and of
CD19+/CCR10+ lymphocytes were augmented in HIV patients
(p = 0.027 and 0.024, respectively) and in ESN (p= 0.026 and
0.012, respectively) compared to HC (Figure 3). In contrast with
these findings, CCR9-expressing lymphocytes were similar in all
the individuals analyzed (data not shown).
Surface density of CCR3 and CCR10 on CD19+ cells
in ESN, HC, and HIV individuals
Evaluation of the mean fluorescence intensity (MFI), a relative-
measure of the surface density on a cellular level, revealed
that CCR3 MFI on CD19+ cells was significantly augmented
in ESN compared to both HIV patients (0.021) and HC (0.034)
but was similar between HIV and HC subjects. CCR10 MFI on
CD19+ lymphocytes was higher in ESN and HIV compared to
HC (ESV vs. HC p=0.019) (Figure 4). Also in this case, CCR9
MFI was comparable among all groups examined (data not
shown).
Salivary and BM concentration of CCL28 and
HIV-specific IgA are correlated
CCL28 chemoattracts IgA-ASC in the MLP and in the mammary
gland; mucosal HIV-specific IgA are observed in both HIV
infection and exposure. We verified the presence of possible
correlations between HIV-specific IgA and CCL28 both in saliva
and BM in the individuals enrolled in the study. Results showed
that a significant correlation indeed exists between these two
parameters both in saliva (spearman rank order correlation
coefficient r = 0.44 p= 0.016) and BM (spearman rank order
correlation coefficient: r = 0.26 p= 0. 036).
Administration of CCL28 augments rectal IgA in
mice
The gastro-intestinal MLP is the first site of massive HIV
replication during primary HIV infection; this phenomenon is
associated with a dramatic early destruction of CD4+ memory T
lymphocytes. Elicitation of adaptive mucosal immunity could
therefore have an important beneficial effect in the prevention of
the establishment of HIV infection. As the results herein showed
that increased CCL28 are correlated with augmented concentra-
tions of HIV-specific IgA, we verified whether immunization of
mice with a VSV vector in the presence of CCL28 could have
resulted in an increase of IgA-ASC in the GI MLP.
Figure 3. Expression of CCR3 and CCR10 on CD19+ B lymphocytes. Upper panels: CCR3-expressing, CD19+ B lymphocytes in peripheral blood.
Lower panels: CCR10-expressing, CD19+ B lymphocytes in peripheral blood. Representative results as well as median values, standard deviations, and
statistically significant differences are shown. Thirty-nine HIV-exposed seronegative individuals (ESN), 40 HIV-infected individuals (HC), and 30 HIV-
uninfected healthy controls (HC) were analyzed.
doi:10.1371/journal.pone.0000969.g003
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CD138+ plasmacells were clearly identified by a immunopositive
staining at the cytoplasmicmembrane. Positive cells were localized in
the lamina propria of colonic mucosa, isolated or grouped in small
clusters. Results, presented in Figure 5, demonstrated that the
number of CD138+cells was higher in VSV-CCL28 mice than in
saline, VSV-alone, or CCL28 animals. IgA+ plasmacells were
identified by immunopositive staining in the cytoplam of cells with
plasmacell-like morphology. In VSV+CCL28 mice, IgA+ cells were
numerous and grouped in clusters within the lamina propria of
colonic mucosa (mean number and S.D. of IgA+ plasma-
cells = 69617; p vs. all other groups ,0.001). In VSV-alone (34+7
IgA+ plasmacells), saline alone (22+15 IgA+ plasmacells), or CCL28
alone (31+13 IgA+ plasmacells) mice, only rare IgA+ cells were
identified by immunohistochemistry; they were isolated in the
lamina propria of the colon and not clustered. These results suggest
a potential usefulness for CCL28 as a mucosal-directed adjuvant.
DISCUSSION
IgA are mostly mucosal antibodies that are responsible for the first
line of defence of adaptive immunity against pathogens [30–34].
High concentrations of HIV-specific mucosal IgA have been
described in both HIV-infected [16–19] and HIV-exposed but
uninfected individuals [20–24]. HIV-specific IgA seen in these two
groups were nevertheless shown to be qualitatively different: IgA
of ESN recognize epitopes different from those seen in HIV-
infected individuals [35], are capable of inhibiting virus transcy-
tosis through epithelial layers in vitro [36. 37], and have a potent
neutralizing activity [38,39]. These qualitative differences not-
withstanding, IgA-secreting plasma cells (IgA-ASC) are chemo-
attracted in the mucosal lamina propria by distinctive CC
chemokines called CCL28, or MEC, and CCL25, or TECK [1–
15]. In the attempt to verify whether a correlation does exist
between augmented concentrations of mucosal IgA in HIV
exposure/infection and increased quantities of CCL28, we
measured CCL28, CCL25 and surface expression of CCL28
and CCL25-binding receptors in ESN, HIV-infected patients, and
HC. Results shown here indicate that the CCL28-dependent, but
not the CCL25-dependent chemotactic circuit is upregulated in
HIV exposure and infection, therefore justifying the augmented
mucosal concentrations of IgA seen in this condition.
CCL28 was measured in different mucosal secretions: breast
milk and saliva. As CCL28 was repeatedly shown to play a role in
Figure 4. CCR3 and CCR10 mean fluorescence intensity on CD19+ B lymphocytes. Median fluorescence intensity (MFI). Panel A: CCR3+/CCD19+ B
lymphocytes; panel B: CCR10+/CCD19+ B lymphocytes. Median values, standard deviations, and statistically significant differences are indicated.
Thirty-nine HIV-exposed seronegative individuals (ESN), 40 HIV-infected individuals (HC), and 30 HIV-uninfected healthy controls (HC) were analyzed.
doi:10.1371/journal.pone.0000969.g004
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the migration of IgA-ASC in mammary and salivary glands [1–15]
it is not totally unexpected that the concentrations of this factor
were higher in both sites in HIV infection and exposure, two
conditions characterized by increased IgA concentrations. It could
apparently be more surprising that CCL28 was augmented in
serum, and that circulating CD19+ cells express more frequently,
and at a higher density, CCR3 and CCR10. These results
nevertheless become more clear considering that lymphocyte
recirculation between tissues and blood compartments is a defining
feature of the immune system. The up regulation of CCR3 and
CCR10 observed on circulating CD19+ lymphocytes could thus
be dependent on the recirculation of lymphocytes between the
mucosal and haematic compartments Analogously, the augmented
concentrations of CCL28 observed in the mucosal tissues were
reflected in the higher quantities of plasmatic CCL28, that,
although one fold lower than what is observed in saliva, still
showed significant differences when ESN and HIV individuals
were compared to healthy controls. It remains to be determined
whether the expression of CCR3 and CCR10 in CD19+
lymphocytes isolated from mucosal secretions will be augmented
as well in HIV infection and exposure.
IgA are the first and main defensive line used by adaptive
immunity at the mucosal level. Not surprisingly, in HIV-infected
patients, IgA, but not IgG prevent virus penetration into mucosal
targets, thus prevent the establishment of infection [40]. In this
light it seems important that CCL28 concentration in breast milk
were positively correlated with better survival in Zambian breast-
fed and vertically HIV-infected children. These children were
enrolled in a protocol (Zambia Exclusive Breastfeeding Study;
ZEBS) and randomized to either stop breastfeeding 4 months after
birth or to continue breastfeeding. Recent analyses have shown
that HIV-infected children who stop breastfeeding had a very high
risk of dying shortly after interruption of breastfeeding (Sinkala,
M., et al. No benefit of early cessation of breastfeeding at 4 months
on HIV-free survival of infants born to HIV-infected mothers in
Zambia: the Zambia Exclusive Breastfeeding Study. 14th Confer-
ence on Retroviruses and Opportunistic Infections. February 25–
28, 2007. Los Angeles, CA.) It could be argued that this mortality
is secondary to withdrawal from the positive effect of BM-
containing IgA and CCL28 at a time of life when the immune
response is still immature. Finally, the correlation between CCL28
and HIV-specific IgA in BM described herein could also justify the
observation that children who acquire HIV through breastfeeding
have a better prognosis than children who acquire it at delivery or
during pregnancy [41].
Recent studies have demonstrated that the gut associated
lymphoid tissue (GALT) contains the vast majority of T cells in the
body, and that GALT is the preferential target for HIV replication
during the acute phase of HIV disease [42–44]. This phenomenon
results in a massive and precocious destruction of CD4+ T cell that
strongly impacts on the pathogenesis of HIV infection [42–44].
These observations have further strengthened the importance and
urgency of developing mucosal vaccine for the prevention of HIV
infection [45,46]. Based on the result shown here, we decided to
verify whether immunization in the presence of CCL28 would
have had a significant effect on mucosal IgA at the gastro-intestinal
(GI) level. This hypothesis was indeed fulfilled by the observation
that IgA-ASC were significantly increased in the GI lamina
propria of mice that were immunized with VSV in the presence of
CCL28. Although preliminary, these results suggest that the use of
CCL28 as an adjuvant could result in a beneficial modulation of
mucosal immunity. Experiments are in progress in which the
biologic effect of CCL28 is further analyzed in animal models.
Tissue-specific migration of lymphocytes is tightly regulated by
a complex network of chemokines. CCL28 has been shown to
direct homing of ASC to the gastro-intestinal and the upper aero-
digestive as well as to the mammary glands [1–15]. CCL28 binds
to CCR3 and CCR10; CCR10 in particular is considered to be
Figure 5. Effect CCL28 on colon plasmacells and IgA of VSV-immunized mice. Upper panels: CD138+ plasmacells; Lower panels: IgA+ plasmacells.
Left column: Balb/c mice immunized with VSV alone; right column: Balb/c mice immunized with VSV in the presence of CCL28. 5 mice/group were
vaccinated. Representative results obtained in the lamina propria of colon mucosa (2-cm specimens from the anus toward the left colon) are
presented.
doi:10.1371/journal.pone.0000969.g005
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a unifying chemokine receptor that plays a pivotal role in homing
of plasmablasts to extra-intestinal effector sites [1–15]. The ability
of the CCL28-CCR3/CCR10 circuit to chemoattract ASC into
multiple mucosal sites has indeed been a founding element of the
concept of a common mucosal immune system, and very recent
results indicate that CCL28 has a broad and unifying role in the
physiology of the mucosal IgA immune system. It might therefore
not be surprising that the CCL28 but not the CCL25 circuit is
upregulated in HIV infection and exposure.
The results herein confirm the hypothesis that CCL28 has
a hierarchically dominant role in the modulation of adaptive
immune responses at the mucosal level and suggest that CCL28
could be useful in the design of mucosal vaccine approaches
finalized at the prevention of HIV infection.
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